RxDoctor Payments Data

Sumitra Patel

Psychiatric/Mental Health · Pulaski, TNNPI 1003497876

Payments from drug & device makers

$4,154in general payments, 2019–2025

Across 259 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$646
  • AbbVie$534
  • Alkermes, Inc.$530
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$426
  • Teva Pharmaceuticals USA, Inc.$401
  • Otsuka America Pharmaceutical, Inc.$391
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$4,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,154 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$13,174
Medicare patients
55
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl94$145,863
RexultiBrexpiprazole46$66,955
Invega SustennaPaliperidone Palmitate18$57,673
CaplytaLumateperone Tosylate20$34,266
Risperdal ConstaRisperidone Microspheres14$24,159
TrintellixVortioxetine Hydrobromide44$21,588
Aripiprazole124$12,967
Lurasidone Hcl66$6,508
Quetiapine Fumarate305$6,102
Venlafaxine Hcl ErVenlafaxine Hcl162$5,616
Trazodone Hcl382$5,177
Buspirone Hcl245$4,824
Hydroxyzine Hcl146$4,328
Desvenlafaxine Succinate ErDesvenlafaxine Succinate63$3,493
Ziprasidone Hcl51$3,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$534$145,86394 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$646$81,83232 claims
Otsuka America Pharmaceutical, Inc.Rexulti$391$66,95546 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$426$34,26620 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$32$21,58844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Pulaski

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →